KATHERINE trial updates for HER2-positive breast cancer

Highlights from ESMO 2019

MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

Using PARP inhibitors to improve quality of life for patients with metastatic breast cancer

Breast cancer highlights from ESMO 2019

Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer

Comment: Veliparib with carboplatin and paclitaxel in advanced gBRCA-positive breast cancers

KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer

MONALEESA-3: Ribociclib plus fulvestrant in advanced breast cancer

Improvement in OS with abemaciclib plus fulvestrant in pre-, peri- and postmenopausal HR-positive, HER2-negative advanced breast cancer resistant to hormonal therapy

Comment: Keynote 522 trial